reports
- Anthony Dick
- Michael Foundoukidis
Alpha Metallurgical Resources Inc: 1 director
A director at Alpha Metallurgical Resources Inc bought 25,000 shares at 176.226USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
- Guy Sips
Amoéba Announcing its first order from its partner Koppert
We welcome Amoéba announced its first order from its partner Koppert. As a result Amoéba delivered on its promise to become a commercial company. Recall that Amoéba's biocontrol activities are now structured around its subsidiary Green 4 Agro. Amoéba stressed that this first order is proof of the promising nature of its partnership with Koppert. We reiterate our Buy rating and € 1.5 Target Price.
2025 full year results
2025 full year results 2025 full year results EBITDA and capacity targets achieved With SPRING: activities refocused, leaner organization and reduction in the number of countries 2025 full year results Turnover: +16% at constant exchange rates to 588 million euros, driven in particular by growth in third-party Services (+70%)EBITDA: 211.31 million euros in line with the target announced in September2 (between 200 and 220 million euros), stable at constant exchange rates compared to 2024, including the impacts of curtailment in BrazilNet loss (group share): at -128.1 million euros due t...
RESULTATS ANNUELS 2025
RESULTATS ANNUELS 2025 RESULTATS ANNUELS 2025 Objectifs d’EBITDA et de capacité atteints Avec SPRING : activités recentrées, organisation allégée et réduction du nombre de pays Résultats annuels 2025 Chiffre d’affaires : +16% à taux de change constants à 588 millions d’euros, notamment porté par la croissance des Services pour clients tiers (+70%)EBITDA : 211,31 millions d’euros en ligne avec l’objectif annoncé en septembre2 (entre 200 et 220 millions d’euros), stable à taux de change constants par rapport à 2024, intégrant les impacts de l’écrêtement au BrésilPerte nette (part du gro...
dsm-firmenich announces share repurchase program to cover share plans ...
dsm-firmenich announces share repurchase program to cover share plans and reduce capital Press Release dsm-firmenich announces share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), March 12, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, today starts a new program to repurchase ordinary shares for a total amount of €540 million, of which €500 million to reduce its issued capital, and €40 million to cover commitments under the Group’s share-based compensation plans. This follows the earlier announcement on ...
Pharming Group reports fourth quarter and full year 2025 financial res...
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by 15% to US$106.5 million, compared to the fourth quarter 2024RUCONEST® full year revenue increased by 26% to US$317.9 million and fourth quarter revenue increased by 9% to US$86.7 millionJoenja® revenue increased by 29% to US$58.2 million and fourt...
Handelsupdate für das Geschäftsjahr 2025
Handelsupdate für das Geschäftsjahr 2025 Ad-hoc-Mitteilung gemäss Art. 53 KR AGAMREE setzt starke Geschäftsentwicklung fort und erzielt Umsatzwachstum von 98% Pratteln, Schweiz, 12. März 2026 – Santhera Pharmaceuticals (SIX: SANN) gibt heute ein Handelsupdate für das Geschäftsjahr 2025 bekannt. Dario Eklund, CEO von Santhera, sagte: “Die starke Geschäftsdynamik, die wir bei AGAMREE® beobachten, spiegelt die zunehmende Akzeptanz in unseren europäischen Kernmärkten und bei unseren globalen Partnern wider, wodurch weltweit mehr Patienten mit Duchenne-Muskeldystrophie Zugang zu die...
Full Year 2025 Trading Update
Full Year 2025 Trading Update Ad hoc announcement pursuant to Art. 53 LR AGAMREE continues to build strong commercial momentum, delivering 98% revenue growth Pratteln, Switzerland, March 12, 2026 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2025. Dario Eklund, CEO of Santhera, said: “The strong commercial momentum we are seeing with AGAMREE® reflects growing adoption across our core European markets and through our global partners, expanding access for more patients with Duchenne muscular dystrophy worldwide. As we continue to broaden our geo...
dsm-firmenich outlines action plan at Investor Event to accelerate per...
dsm-firmenich outlines action plan at Investor Event to accelerate performance, following completion of transformation Press Release dsm-firmenich outlines action plan at Investor Event to accelerate performance, following completion of transformation Kaiseraugst (Switzerland), Maastricht (Netherlands), March 12, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, is today holding an Investor Event in London for institutional analysts and investors from 9:30am until 1:30pm GMT. The event will be broadcast live via . Dimitri de Vreeze, Chief Executive Officer, commented: “Ov...
DNO Releases 2025 Annual Report
DNO Releases 2025 Annual Report Oslo, 12 March 2026 – DNO ASA, the Norwegian oil and gas operator, today released its 2025 Annual Report together with its Remuneration Report and Annual Statement of Reserves and Resources. The reports are attached as downloadable files and also available on the Company’s website – For further information, please contact:Media: Investors: – DNO ASA is a Norwegian oil and gas operator active in the Middle East, the North Sea and West Africa. Founded in 1971, DNO is Norway’s oldest oil company and the first to list on the Oslo Stock Exchange in 1981. ...
Melexis Strengthens Commitment to China with New Wholly Foreign-Owned ...
Melexis Strengthens Commitment to China with New Wholly Foreign-Owned Enterprise (WFOE) and Autonomous Regional Organization Tessenderlo-Ham, Belgium – 12 March 2026 – (Euronext Brussels: MELE), a global leader in micro-electronic semiconductor solutions, today announced the formal establishment of Melexis Integrated System (Shanghai) Co., Ltd, a Wholly Foreign-Owned Enterprise (WFOE). This is an important milestone in the company's China strategy, alongside a redesign of its regional organization. This development represents a critical step in Melexis’ global strategy, where accelerating...
JCDecaux : Full-Year 2025 results, strong performance with operating m...
JCDecaux : Full-Year 2025 results, strong performance with operating margin rate and free cash flow already exceeding 2026 targets Full-Year 2025 results Strong performance with operating margin rate and free cash flow already exceeding 2026 targets Paris, March 12th, 2026 Solid underlying revenue growth +0.8% reported growth, at €3,967.1m revenue in 2025, +1.8% organic growth, +3.2% excluding the impact of the 2024 Paris Olympic and Paralympic Games and UEFA Euro+1.6% organic growth in Q4 above our expectations, a record quarter, including +3.1% organic growth for advertising revenue...
JCDecaux : Résultats annuels 2025, performance très solide avec un tau...
JCDecaux : Résultats annuels 2025, performance très solide avec un taux de marge opérationnelle et un cash-flow disponible dépassant déjà les objectifs de 2026 Résultats annuels 2025 Performance très solide avec un taux de marge opérationnelle et un cash-flow disponible dépassant déjà les objectifs de 2026 Paris, le 12 mars 2026 Croissance sous-jacente solide du chiffre d'affaires +0,8 % croissance publiée, à 3 967,1 millions d'euros de chiffre d'affaires en 2025, +1,8 % croissance organique, +3,2 % hors impact des Jeux Olympiques et Paralympiques de Paris 2024 et de l'Euro UEFA+1,6 %...
Moody's Ratings upgrades ratings on notes from Metro Finance 2025-1 Tr...
Moody's Ratings (Moody's) has upgraded the ratings on four classes of notes issued by Metro Finance 2025-1 Trust. IMPORTANT NOTICE: MOODY'S RATINGS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS. SUCH USE WOULD BE RECKLESS AND INAPPROPRIATE. SEE FULL DISCLAIMERS BELOW. The affecte...
- ABGSC IT Research
- Daniel Thorsson
- Nikola Kalanoski
- Simon Granath
- Martial Descoutures
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.